

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A composition comprising ~~(i) Mycobacterium w~~
Mycobacterium w and/or constituent(s) thereof as an adjuvant, and/or (ii) an antigen, and (iii) in a
pharmaceutically acceptable carrier that causes an eliciting enhanced antigen associated immune
response of the antigen.
2. (Previously presented) A composition as claimed claim 1, further comprising
other adjuvants.
3. (Currently amended) A composition as claimed in claim 1, wherein the
~~Mycobacterium w~~ Mycobacterium w comprises a killed Mycobacterium w.
4. (Currently amended) A composition as claimed in claim 3, wherein the killed
~~Mycobacterium w~~ Mycobacterium w is killed by heat, radiation, preferably by autoclaving.
5. (Currently amended) A composition as claimed in claim 1, wherein the
constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained by sonication.
6. (Currently amended) A composition as claimed in claim 1, wherein the
constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained by high pressure cell
fractionator.
7. (Currently amended) A composition as claimed in claim 1, wherein the
constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained by osmotic pressure
ingredient gradient.

8. (Currently amended) A composition as claimed in claim 1, wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained from the ~~Mycobacterium w~~ Mycobacterium w by extraction.

9. (Currently amended) A composition as claimed in claim 1, wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are extracted from the ~~Mycobacterium w~~ Mycobacterium w by organic solvents.

10. (Currently amended) A composition as claimed in claim 1, wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are extracted using solvents selected from the group consisting of chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, and hexane.

11. (Currently amended) A composition as claimed in claim 1 wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained by enzymatic treatment.


12. (Currently amended) A composition as claimed in claim 1, wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are obtained by using enzyme lyticase and/or pronase.

13. (Currently amended) A composition as claimed in claim 1, wherein the constituent(s) of ~~Mycobacterium w~~ Mycobacterium w is/are preferably substantially water insoluble.

14. (Currently amended) A composition as claimed in claim 1, wherein the ~~Mycobacterium w~~ Mycobacterium w is a non-pathogenic, fast growing, cultivable, atypical Mycobacterium, with biochemical properties and growth characteristics ~~resembling~~ substantially similar those belonging to Runyons group IV class of Mycobacteria.

15. (Currently amended) A composition as claimed in claim 1, wherein the

~~Myco~~~~bacterium w~~ Mycobacterium w is urease negative, does not hydrolyse ~~tween 80~~ a compound of the formula below, does not produce niacin, and provides positive response to nitrate reduction test,



16. (Currently amended) A composition as claimed in claim 1, wherein the

~~Myco~~~~bacterium w~~ Mycobacterium w and/or constituents thereof are mixed, formulated, conjugated, primed, fused and/or linked with ~~an~~ the antigen.

17. (Currently amended) A composition as claimed in claim 1, wherein the antigen(s)

is selected from the group consisting of one or more peptides, one or more polypeptides, one or more cells, one or more cell extracts, one or more polysaccharides, one or more polysaccharide conjugates, one or more lipids, one or more glycolipids, one or more carbohydrates, one or more proteins, one or more viruses, one or more viral extracts, and one or more ~~antigen-encoded in~~ nucleic acids.

18. (Currently amended) A composition as claimed in claim 1, wherein the antigen(s) is

~~derived~~ isolated from an infectious agent selected from the group consisting of virus, bacterium, fungus and parasites.

19. (Previously presented) A composition as claimed in claim 1, wherein the

antigen(s) is a tumor associated antigen.

20. (Previously presented) A composition as claimed in claim 1, wherein the antigen is a tumor specific antigen.

21. (Previously presented) A composition as claimed in claim 1, wherein the antigen(s) is an allergen.

22. (Currently amended) A composition containing a pharmaceutically effective amount of the composition as claimed in claim 1; sufficient to induces or enhance immunogenicity of antigen(s) wherein the composition when administered to a mammal induces or enhances immunogenicity of antigen(s).

23. (Currently amended) A composition containing a pharmaceutically effective amount of the composition as claimed in claim 1; sufficient to ~~wherein the composition prevents~~ prevent diseases in mammal ~~by inducing or enhancing immunogenicity of antigen(s).~~

24. (Currently amended) A composition containing a pharmaceutically effective amount of the composition as claimed in claim 1; sufficient to ~~wherein the composition when administered to a diseased mammals induces or enhances immunogenicity of antigen (s) resulting in decreased~~ decrease morbidity ~~&and~~ and mortality associated with disease.

25. (Currently amended) A composition containing a pharmaceutically effective amount of the composition as claimed in claim 1; sufficient to ~~wherein the composition induce or enhance immunogenicity when combined with another therapy to a diseased mammal induces or enhances immunogenicity of an antigen (s) resulting in decreased morbidity and morlatity associated with diseases by inducing or enhancing immunogenicity of an antigen(s).~~

26. (Currently amended) A composition containing a pharmaceutically effective amount of the composition as claimed in claim 1; sufficient to wherein the composition induces induce an immune response.

27. (Canceled)

28. (Canceled)

29. (Currently amended) ~~Mycobacterium w~~ Mycobacterium w and/or a constituent thereof as an adjuvant to an antigen.